Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDAC2 | P45880 | 1/20 | 0.58 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.45 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633693 | 0.93 | VDAC2 (0.49) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633710 | 0.93 | VDAC2 (0.49) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633593 | 0.93 | VDAC2 (0.49) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633694 | 0.93 | VDAC2 (0.49) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633586 | 0.93 | VDAC2 (0.49) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633734 | 0.92 | VDAC2 (0.50) | VDAC2SLC7A11HTR7CXCR3 | |
| SCHEMBL13633679 | 0.90 | VDAC2 (0.51) | VDAC2SLC7A11HIF1AHTR7 | |
| SCHEMBL13638609 | 0.90 | ALDH1A1 (0.46) | VDAC2SLC7A11CXCR3 | |
| SCHEMBL13633747 | 0.89 | VDAC2 (0.60) | VDAC2SLC7A11HIF1AHTR7 | |
| SCHEMBL13633584 | 0.88 | VDAC2 (0.71) | VDAC2SLC7A11HIF1AHTR7CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | VDAC2 3980/4885SLC7A11 1250/4885HIF1A 928/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | VDAC2 553/4885SLC7A11 906/4885HIF1A 726/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | VDAC2 2/4885SLC7A11 565/4885HIF1A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.